PA
VRCA icon

Parallel Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

Parallel Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-18
Closed -$1.28K – 3475
2024
Q2 		$1.28K Buy
+18
New +$1.38K ﹤0.01% 2904
2021
Q3 		– Sell
-9
Closed -$1K – 3280
2021
Q2 		$1K Buy
+9
New +$1.09K ﹤0.01% 2843

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Parallel Advisors's VRCA Position: Q3 2024 in Review

Parallel Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2024, closing a stake of 18 shares — an estimated $1.28K sold.

Parallel Advisors first reported a position in VRCA in Q2 2021 and held it in 2 quarters. The position peaked at $1.28K in Q2 2024. 79 funds tracked by Wall St. Rank hold VRCA as of Q3 2024.

  • Parallel Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Parallel Advisors sold 18 Verrica Pharmaceuticals shares in Q3 2024, an estimated $1.28K.
  • Parallel Advisors first reported a position in Verrica Pharmaceuticals in Q2 2021 and held it in 2 quarters.
  • Parallel Advisors's Verrica Pharmaceuticals position peaked at $1.28K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2024.

Based on Parallel Advisors's 13F filing for Q3 2024, filed 13 Nov 2024.